Randall, Jamie
Hunt, Allison L.
Nutcharoen, Aratara
Johnston, Laura
Chouraichi, Safae
Wang, Hongkun
Winer, Arthur
Wadlow, Raymond
Huynh, Jasmine
Davis, Justin
Corgiat, Brian
Bateman, Nicholas W.
Deeken, John F.
Petricoin, Emanuel F.
Conrads, Thomas P.
Cannon, Timothy L.
Article History
Received: 16 November 2023
Accepted: 28 February 2024
First Online: 20 March 2024
Declarations
:
: WIRB-Copernicus Group Institutional Review Board (WCG IRB) approved this study. All participants provided written informed consent.
: T.P.C is a ThermoFisher Scientific, Inc SAB member and receives research funding from AbbVie. E.F.P is a consultant for Theralink Technologies, Inc., receives research funding from Genentech, Pfizer, AbbVie, Mirati, Springworks Pharmaceuticals, Diciphera Pharmaceuticals, and is a co-inventor of the RPPA technology described herein and receives royalties on the related license agreements with Theralink Technologies, Inc.